Amneal Pharmaceuticals, Inc. AMRX Specialty — Net revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s specialty — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — net revenue of $133.27M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — net revenue increased by 23.1% year-over-year, from $108.3M to $133.27M.
- What does specialty — net revenue mean?
- The total gross sales generated by the specialty pharmaceutical segment after accounting for returns, allowances, and rebates. This is a primary indicator of the segment's market demand and the commercial success of its branded pharmaceutical products.